Accessibility Menu
Anbio Biotechnology logo

Anbio Biotechnology(NASDAQ) NNNN

Market Cap$298.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)+18%
5 YearN/A
1 Year-86%
1 Month-28%
$6.84
-6.67%
-0.49Today
After hours$6.97+$0.13 (+1.89%)
Anbio Biotechnology last closing stock price
MetricPriceDate
Last closeUSD 6.812026-08-21
Anbio Biotechnology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-22.08%USD 8.742026-08-14
1 month-27.94%USD 9.452026-07-22
3 month-79.06%USD 32.522026-05-22
Year to date-77.35%USD 30.072025-12-31
1 year-86.21%USD 49.392025-08-21
Since inception+18.02%USD 5.772025-02-19

Anbio Biotechnology Financials at a Glance

Market Cap

$298.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$14.30M

Net Income (TTM)

$7.16M

EPS (TTM)

$0.16

P/E Ratio

41.60

Dividend

$0.00

Beta (Volatility)

0.32 (Low)

Price

$6.84

Volume

581

Open

$7.20

Previous Close

$6.81

Daily Range

$6.61 - $7.35

52-Week Range

$6.61 - $51.33

Estimated Earnings Date

Jul 7, 2026

NNNN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Anbio Biotechnology

Anbio Biotechnology is a global supplier of in vitro diagnostics (IVD) products, established in 2021 and headquartered in Frankfurt am Main, Germany. The company specializes in advanced diagnostic solutions, including rapid antigen tests for SARS-CoV-2, and operates across multiple international markets.

Products and Services
  • Rapid antigen tests for SARS-CoV-2 and influenza A/B
  • Advanced diagnostic technologies like LAMP and RT-PCR
  • Solutions for over-the-counter sales and point-of-care testing
Growth Outlook
  • Revenue of $4.74 million in Q4 2025, showing strong demand
  • Trailing twelve months (TTM) gross profit margin of 81.5%
  • Significant international market expansion opportunities in healthcare
Financial Highlights
  • Net income of $3.04 million in Q4 2025, reflecting profitability
  • Current ratio of 344.31, indicating strong liquidity
  • Return on equity (ROE) of 27.49%, showcasing effective management
Anbio Biotechnology has positioned itself as a key player in the medical instruments and supplies industry, particularly in the diagnostics sector. The company's innovative product offerings and robust financial performance highlight its potential for growth. With a strong focus on research and development, Anbio is well-equipped to meet the increasing demand for diagnostic solutions globally. The recent quarterly results indicate a solid revenue stream and profitability, which may attract investor interest. The company's high liquidity ratio suggests it can effectively manage its short-term obligations, while a strong return on equity reflects efficient use of shareholder funds. Overall, Anbio Biotechnology presents a compelling opportunity for those interested in the healthcare sector.
AI Generated • Aug 18, 2026

Industry

Biotechnology

Sector

Health Care

Employees

27

CEO

Michael Lau, PhD, MBA

Website

www.anbio.com

Headquarters

Frankfurt am Main, HE 60327, DE

NNNN Financials

Key Financial Metrics (TTM)

Gross Margin

86.10%

Operating Margin

65.20%

Net Income Margin

72.09%

Return on Equity

27.49%

Return on Capital

19.13%

Return on Assets

28.07%

Earnings Yield

2.40%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$298.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

43.89M

Volume

581

Avg. Volume

66.10K

Financials (TTM)

Gross Profit

$12.28M

Operating Income

$5.94M

EBITDA

$5.15M

Operating Cash Flow

$2.25M

Capital Expenditure

$0.00

Free Cash Flow

$2.25M

Cash & ST Invst.

$11.90M

Total Debt

$0.00

Anbio Biotechnology Performance Analysis

Anbio Biotechnology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 24,744,825372.7%
20232023-12-31USD 7,256,437-70.7%
20242024-12-31USD 8,853,79722.0%
20252025-12-31USD 9,758,63710.2%
Anbio Biotechnology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q22025-06-30N/A
Q32025-09-30-59.4%
Q42025-12-31133.3%
Anbio Biotechnology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.25250.9%
20232023-12-31USD 0.06-76.8%
20242024-12-31USD 0.065.4%
20252025-12-31USD 0.16171.2%
Anbio Biotechnology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q22025-06-30N/A
Q32025-09-30-68.6%
Q42025-12-31133.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$4.74M

-25.1%

Gross Profit

$3.86M

-8.7%

Gross Margin

81.49%

N/A

Market Cap

$298.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$11.07M

N/A

Employees

27

N/A

Net Income

$3.04M

-21.8%

EBITDA

$2.80M

-28.0%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$11.90M

+15.4%

Total Debt

$0.00

N/A

Accounts Receivable

$3.66M

-20.8%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

28.07%

N/A

Return on Invested Capital

25.46%

N/A

Free Cash Flow

$0.00

+100.0%

Operating Cash Flow

$0.00

+100.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SNDLSNDL Inc.
$1.37+3.01%
CYHCommunity Health Systems, Inc.
$3.01+1.01%
CLPTClearPoint Neuro, Inc.
$15.39+1.32%
GOSSGossamer Bio, Inc.
$0.15-1.78%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$120.60-0.01%
IBITiShares Bitcoin Trust
$43.68+0.06%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$47.03+0.02%
MSTRStrategy
$119.25+0.06%

Questions About NNNN

What is the current price of Anbio Biotechnology?

Anbio Biotechnology is trading at $6.81 per share.

What is the 52-week range for Anbio Biotechnology?

Over the past 52 weeks, Anbio Biotechnology has traded between $6.61 and $51.33.

How much debt does Anbio Biotechnology have?

As of the most recent reporting period, Anbio Biotechnology reported total debt of $0.00.

How much cash does Anbio Biotechnology have on hand?

Anbio Biotechnology reported $9.12M in cash and cash equivalents in its most recent financial results.

What is Anbio Biotechnology’s dividend yield?

Anbio Biotechnology does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services